Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | APLNR | P35414 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | CALCA | P06881 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL968024 | 0.96 | APLNR (0.41) | GSK3AGSK3BAPLNRTP53RAB9A | |
| SCHEMBL967067 | 0.94 | ALOX12 (0.41) | APLNRTP53MAPTRAB9AL3MBTL1 | |
| SCHEMBL967602 | 0.90 | TP53 (0.39) | APLNRTP53MAPTRAB9AL3MBTL1 | |
| SCHEMBL969907 | 0.90 | NPSR1 (0.39) | APLNRTP53MAPTRAB9AL3MBTL1 | |
| SCHEMBL965443 | 0.88 | APLNR (0.37) | APLNRTP53MAPTRAB9AL3MBTL1 | |
| SCHEMBL12919917 | 0.88 | HSP90AA1 (0.38) | GSK3AGSK3BMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL3559789 | 0.88 | TP53 (0.39) | APLNRTP53MAPTRAB9AL3MBTL1 | |
| SCHEMBL970508 | 0.87 | L3MBTL1 (0.42) | APLNRTP53MAPTRAB9AL3MBTL1 | |
| SCHEMBL966772 | 0.86 | MAPT (0.39) | APLNRTP53MAPTRAB9AL3MBTL1 | |
| SCHEMBL966556 | 0.85 | GSK3B (0.40) | GSK3AGSK3BTP53RAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1622615-A4 | NAPHTHYRIDINE INTEGRASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2009-02-18 | — | — | EP | claimed |
| US-20070142365-A1 | Naphthyridine integrase inhibitors | GSK LLC | 2007-06-21 | — | — | US | claimed |
| EP-1622615-A2 | NAPHTHYRIDINE INTEGRASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-02-08 | — | — | EP | claimed |
| WO-2004101512-A2 | NAPHTHYRIDINE INTEGRASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-11-25 | — | — | WO | claimed |
| US-20110003794-A1 | Naphthyridine Integrase Inhibitors | GSK LLC | 2011-01-06 | — | — | US | disclosed |
| US-20110003794-A1 | Naphthyridine Integrase Inhibitors | GSK LLC | 2011-01-06 | — | — | US | disclosed |
| US-20110003794-A1 | Naphthyridine Integrase Inhibitors | GSK LLC | 2011-01-06 | — | — | US | disclosed |
| US-7812016-B2 | Naphthyridine integrase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2010-10-12 | — | — | US | disclosed |
| US-7812016-B2 | Naphthyridine integrase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2010-10-12 | — | — | US | disclosed |
| US-7812016-B2 | Naphthyridine integrase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2010-10-12 | — | — | US | disclosed |
| US-20070142365-A1 | Naphthyridine integrase inhibitors | GSK LLC | 2007-06-21 | — | — | US | disclosed |
| US-20070142365-A1 | Naphthyridine integrase inhibitors | GSK LLC | 2007-06-21 | — | — | US | disclosed |
| US-20070142365-A1 | Naphthyridine integrase inhibitors | GSK LLC | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003794-A1 | Naphthyridine Integrase Inhibitors | PCNA, SAMHD1, NTPCR | GSK3A 788/4885GSK3B 779/4885APLNR 2549/4885 |
| US-20070142365-A1 | Naphthyridine integrase inhibitors | PCNA, SAMHD1, NTPCR | GSK3A 788/4885GSK3B 779/4885APLNR 2549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.